RNXT

RenovoRx, Inc. NASDAQ Listed Aug 26, 2021

Healthcare ·Biotechnology ·US · renovorx.com

$0.88

Mkt Cap $30.9M

52w Low $0.70 23.9% of range 52w High $1.45

50d MA $0.94 200d MA $1.02

P/E (TTM) -2.8x

EV/EBITDA -1.8x

P/B 5.8x

Debt/Equity 0.0x

ROE -206.0%

P/FCF -2.7x

RSI (14) —

ATR (14) —

Beta 1.22

50d MA $0.94

200d MA $1.02

Avg Volume 333.0K

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

SIC Code

2834

CIK (SEC)

1574094

Phone

650 284 4433

4546 El Camino Real · Mountain View, CA 94022 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 30, 2026	AMC	-0.08	-0.08	+0.0%	1.07	+1.9%	-5.6%	-4.0%	+1.0%	-4.9%	-3.4%	—
Nov 13, 2025	AMC	-0.08	-0.08	+0.0%	0.97	-8.7%	-23.0%	+7.2%	-2.7%	-6.4%	+6.3%	—
Aug 14, 2025	AMC	-0.08	-0.08	+0.0%	1.24	-19.4%	-22.9%	-1.6%	-2.0%	-5.6%	+2.7%	—
May 15, 2025	AMC	-0.08	-0.08	+0.0%	1.11	+0.0%	+6.3%	+5.1%	-1.6%	+0.0%	+0.8%	—
Mar 31, 2025	AMC	-0.13	-0.12	+7.7%	0.99	-1.0%	-3.0%	+4.2%	-9.0%	-3.1%	-10.4%	—
Nov 13, 2024	AMC	-0.12	-0.10	+16.7%	1.09	+3.7%	+0.0%	+0.0%	-1.8%	+3.7%	+7.2%	—
Aug 13, 2024	AMC	-0.10	-0.10	+0.0%	1.16	+1.7%	-3.4%	-0.9%	+6.3%	-10.2%	+0.0%	—
May 10, 2024	AMC	-0.14	-0.07	+50.0%	1.45	-5.5%	-2.8%	+2.8%	-4.1%	+5.0%	-6.2%	—
Apr 1, 2024	AMC	-0.30	-0.17	+43.3%	1.32	-0.8%	-6.1%	+1.6%	-4.8%	-3.3%	+0.9%	—
Nov 13, 2023	AMC	-0.30	-0.27	+10.0%	1.05	+6.3%	-28.3%	-1.2%	-15.8%	-4.1%	+1.5%	—
Aug 16, 2023	AMC	-0.25	-0.22	+12.0%	1.71	+14.0%	+7.6%	-6.5%	+0.0%	+5.2%	-3.3%	—
May 15, 2023	AMC	-0.25	-0.36	-44.0%	2.23	+0.0%	-0.9%	-5.0%	+2.4%	+0.0%	-5.6%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 9	Ascendiant Capital	Maintains	Buy → Buy	—	$0.94	$0.92	-2.0%	+4.2%	+0.7%	+3.5%	+1.0%	-1.0%
Apr 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$0.90	$0.95	+5.6%	+4.3%	+4.2%	+0.7%	+3.5%	+1.0%
Feb 17	Ascendiant Capital	Maintains	Buy → Buy	—	$0.93	$0.98	+4.9%	+5.0%	+2.0%	-5.9%	-2.9%	-1.2%
Nov 21	Ascendiant Capital	Maintains	Buy → Buy	—	$0.78	$0.79	+1.7%	+2.2%	-1.3%	+10.2%	+2.4%	+3.5%
Aug 25	Ascendiant Capital	Maintains	Buy → Buy	—	$0.94	$0.94	-0.0%	-4.5%	+2.8%	+0.1%	+2.5%	+1.3%
Jun 5	Ascendiant Capital	Maintains	Buy → Buy	—	$1.39	$1.39	+0.0%	+0.7%	-0.7%	-1.4%	-2.2%	+1.5%
May 19	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.18	$1.24	+5.1%	+5.1%	-1.6%	+0.0%	+0.8%	-3.3%
Apr 28	Ascendiant Capital	Maintains	Buy → Buy	—	$0.99	$0.98	-1.0%	-1.8%	-0.2%	-1.0%	+3.1%	+1.0%
Apr 4	HC Wainwright & Co.	Maintains	Buy → Buy	—	$0.91	$0.92	+1.2%	-3.1%	-10.4%	+1.3%	+3.8%	-4.7%
Dec 10	Ascendiant Capital	Maintains	Buy → Buy	—	$1.43	$1.41	-1.4%	-4.2%	+2.9%	-6.4%	-3.0%	-2.3%
Sep 12	Ascendiant Capital	Maintains	Buy → Buy	—	$1.05	$1.10	+4.8%	+1.9%	+5.6%	-6.2%	-4.7%	-2.0%
Nov 15	Maxim Group	Downgrade	Buy → Hold	—	$0.75	$0.78	+3.0%	-1.2%	-15.8%	-4.1%	+1.5%	+2.0%
Aug 18	Roth MKM	Maintains	Buy → Buy	—	$1.84	$1.91	+3.8%	-6.5%	+0.0%	+5.2%	-3.3%	-1.7%
Nov 1	Roth Capital	Maintains	Buy → Buy	—	$5.18	$5.39	+4.1%	+5.4%	+0.2%	-0.7%	+0.2%	-3.3%
Oct 6	Maxim Group	Maintains	Buy → Buy	—	$5.72	$5.80	+1.4%	+3.3%	+4.1%	-7.2%	-3.7%	+2.7%

Data updated apr 26, 2026 11:17pm · Source: massive.com